Korean PD Biotech
Overview
Mermaid diagram (expand to render)
South Korea has established itself as a leading biotechnology hub in Asia, with a particularly strong focus on neuroscience and neurodegenerative disease research. The Korean pharmaceutical and biotech sector has made significant strides in developing novel therapeutics for [Parkinson's disease](/diseases/parkinsons-disease), including cell therapy, gene therapy, small molecule inhibitors, and biologics approaches["@kim2023"].
The Korean government has prioritized neuroscience research through various initiatives, including the Korea Drug Development Fund (KDDF), the K-BIO cluster development program, and partnerships between academic institutions and pharmaceutical companies. This supportive ecosystem has enabled Korean biotechnology companies to advance innovative Parkinson's disease therapies through clinical development["@kbio2025"].
Major Korean PD Companies
Samsung Bioepis
- Headquarters: Incheon, South Korea
- Founded: 2012 (joint venture Samsung + Biogen)
- Focus: Biosimilars, novel biologics, immunotherapy
- Website: samsungbioepis.com
- PD Program: Immunotherapy development targeting neuroinflammation
Samsung Bioepis has expanded beyond its biosimilar foundation to develop novel immunotherapeutics for neurodegenerative diseases. Their approach focuses on modulating the immune response to reduce neuroinflammation, a key pathological feature of Parkinson's disease. The company has established partnerships with international biotech firms to access cutting-edge immunotherapy platforms.
CJ Healthcare
- Headquarters: Seoul, South Korea
- Focus: Novel therapeutics, gastrointestinal and CNS drugs
- Website: cjhealthcare.co.kr
- PD Program: CNS drug development, dopamine receptor modulators
CJ Healthcare has leveraged its expertise in gastrointestinal therapeutics to develop CNS drugs that can cross the blood-brain barrier. Their Parkinson's disease program focuses on novel dopamine receptor agonists with improved side effect profiles compared to existing therapies. The company has conducted Phase 1 clinical trials for their lead PD candidate[@son2023].
Kolon Life Science
- Headquarters: Seoul, South Korea
- Focus: Gene therapy, cell therapy, GMP manufacturing
- Website: kolonls.com
- Notable: GMP manufacturing capabilities, partnership with Novartis
Kolon Life Science is a leader in cell and gene therapy in Korea. Their Parkinson's disease program includes:
- Stem cell therapy: Human mesenchymal stem cells (hMSCs) for dopaminergic neuron replacement
- Gene therapy: AAV-based delivery of neurotrophic factors (GDNF, ARTN)
- Cell encapsulation: Encapsulated cell therapy for sustained drug delivery
The company has completed preclinical studies and is preparing for clinical trials in partnership with international pharmaceutical companies[@lee2022].
Genexine
- Headquarters: Seongnam, South Korea
- Focus: Novel biologics, fusion proteins, immunotherapy
- Website: genexine.com
- Pipeline: Immunotherapy programs, long-acting therapeutics
Genexine specializes in fusion protein technology and has developed a platform for long-acting biologics. Their Parkinson's disease approach includes:
- Immune modulators targeting neuroinflammation
- Long-acting neurotrophic factors
- Bispecific antibodies targeting alpha-synuclein
The company has published preclinical data showing efficacy in animal models of Parkinson's disease[@han2024].
Daewoong Pharmaceutical
- Headquarters: Seoul, South Korea
- Focus: Novel therapeutics, gene therapy, cell therapy
- Website: daewoong.co.kr
- PD Program: Cell therapy, gene therapy, small molecules
Daewoong Pharmaceutical has invested heavily in advanced therapy development for Parkinson's disease:
- Cell therapy: Induced pluripotent stem cell (iPSC)-derived dopaminergic neurons
- Gene therapy: AAV vectors for gene delivery to the brain
- Small molecules: Alpha-synuclein aggregation inhibitors
The company operates a state-of-the-art cell therapy manufacturing facility meeting international GMP standards[@kim2023].
Bukwang Pharmaceutical
- Headquarters: Seoul, South Korea
- Focus: CNS disorders, neuropsychiatry
- Website: bukwang.co.kr
- PD Program: Dopamine agonists, COMT inhibitors, neuroprotective agents
Bukwang Pharmaceutical has a established portfolio in CNS disorders:
- Stalevo (Entacapone): COMT inhibitor already marketed in Korea
- New COMT inhibitors: Next-generation compounds with improved efficacy[@kim2022]
- Dopamine agonists: Novel receptor-selective compounds
- Neuroprotective agents: Disease-modifying drug candidates
The company has completed multiple Phase 2 clinical trials for their Parkinson's disease pipeline[@jung2024].
JW Pharmaceutical
- Headquarters: Seoul, South Korea
- Focus: Innovative therapeutics, CNS, oncology
- Website: jwpharma.co.kr
- PD Program: CNS disorders, drug discovery
JW Pharmaceutical focuses on innovative drug development with an emphasis on CNS disorders. Their Parkinson's disease research includes:
- Novel mechanism targets beyond dopamine replacement
- Disease-modifying approaches targeting alpha-synuclein
- Biomarker development for patient stratification[@yang2023]
Dong-A ST
- Headquarters: Goyang, South Korea
- Focus: Novel pharmaceuticals, biosimilars, CNS therapeutics
- Website: donga-st.co.kr
- PD Program: CNS therapeutics pipeline
Dong-A ST has developed a diversified pharmaceutical portfolio with growing CNS capabilities:
- Parkinson's disease therapeutics in clinical development
- Partnerships with Korean academic institutions
- Focus on improved delivery systems for CNS drugs
Yuhan Corporation
- Headquarters: Seoul, South Korea
- Focus: Pharmaceutical R&D, novel drugs
- Website: yuhan.co.kr
- PD Program: CNS drug development
Yuhan Corporation invests significantly in CNS drug discovery:
- Early-stage Parkinson's disease programs
- Novel therapeutic targets beyond dopaminergic pathways
- Academic collaborations with Korean universities
Hanmi Pharmaceutical
- Headquarters: Seoul, South Korea
- Focus: Novel drug development, metabolic disorders, CNS
- Website: hanmi.co.kr
- Pipeline: CNS programs, metabolic disorders
Hanmi Pharmaceutical is one of Korea's largest pharmaceutical companies with a broad pipeline:
- Parkinson's disease therapeutic candidates
- Long-acting formulations for improved patient compliance
- Research partnerships with international pharmaceutical companies
Japanese PD Companies with Korean Partnerships
Japan has several biotechnology companies developing Parkinson's disease therapies that collaborate with Korean partners or have regional presence in East Asia.
Tree Pharmaceutical Co., Ltd.
- Headquarters: Osaka, Japan
- Focus: Alzheimer's disease, Parkinson's disease
- Website: https://www.treepharma.co.jp
Tree Pharmaceutical is an Osaka-based biotechnology company dedicated to developing novel therapeutics for neurodegenerative diseases. The company focuses on amyloid-beta and alpha-synuclein targeting approaches, leveraging Japan's strong academic research base to advance novel drug candidates through clinical development.
- Key Programs: AD/PD therapeutics targeting protein aggregation, novel small molecules
- Pipeline Status: Active drug discovery programs in preclinical and early clinical stages
- Korean Connection: Potential collaboration with Korean academic institutions for clinical trials
Accerise Inc.
- Headquarters: Tokyo, Japan
- Focus: Structure-based drug design
- Website: https://www.accerise.com
Accerise is a Tokyo-based drug discovery company utilizing structure-based design and computational approaches to develop therapeutics for neurodegenerative diseases. The company's proprietary platform enables rapid optimization of drug candidates targeting previously undruggable proteins involved in neurodegeneration.
- Key Programs: Novel enzyme inhibitors, computational drug design, protein structure-based optimization
- Notable Capabilities: Cryo-EM and X-ray crystallography for structural biology
- Korean Connection: Potential technology licensing to Korean pharmaceutical companies
Kinevo Inc.
- Headquarters: Tokyo, Japan
- Focus: Mitochondrial dysfunction, Neurodegeneration
- Website: https://www.kinevo.co.jp
Kinevo is a Tokyo-based biotechnology company focused on developing therapeutics targeting mitochondrial dysfunction in neurodegenerative diseases. Mitochondrial dysfunction is increasingly recognized as a central mechanism in both Alzheimer's and Parkinson's disease pathogenesis, making this a high-value target area.
- Key Programs: Mitochondrial protectors, neuroprotective agents targeting electron transport chain dysfunction
- Research Focus: Developing compounds that preserve mitochondrial function under conditions of oxidative stress
- Korean Connection: Research collaborations with Korean universities on mitochondrial biology
CureApp, Inc.
- Headquarters: Tokyo, Japan
- Focus: Digital therapeutics
- Website: https://cureapp.jp
CureApp is a Tokyo-based company developing digital therapeutics (DTx) for Alzheimer's disease and Parkinson's disease. The company takes a software-as-medical-device approach, developing smartphone-based interventions that can modify disease progression through cognitive training, behavioral modification, and remote monitoring.
- Key Programs: Digital therapeutics for cognitive impairment, apps for Parkinson's disease management
- Notable Achievement: First digital therapeutic approved for Alzheimer's disease in Japan
- Korean Connection: Digital health partnerships with Korean healthcare systems
Korean PD Research Institutions
Seoul National University
- Strengths: Leading PD research in Korea, world-class neuroscience program
- Facilities: Clinical trials infrastructure, basic research laboratories
- Programs: Alpha-synuclein biology, stem cell therapy, biomarker discovery
- Collaborations: Industry partnerships for drug development
Korea University
- Strengths: Neurobiology research, drug discovery programs
- Focus: Parkinson's disease mechanism research, animal models
- Output: Published research on dopamine signaling, neuroprotection
Yonsei University
- Strengths: [Parkinson](/diseases/parkinsons-disease)'s disease clinical research, biomarker studies
- Facilities: Movement disorder clinic, clinical trial center
- Research: Patient cohorts for biomarker validation, clinical outcomes research[@yang2023]
KAIST
- Strengths: Stem cell research, neuroscience technology development
- Focus: iPSC-derived neurons, organoid models, drug screening platforms
- Innovation: Engineering solutions for neural regeneration
Korea Institute of Science and Technology (KIST)
- Focus: Neurotechnology, brain-computer interfaces
- Research: Neural prosthetics, diagnostic devices for PD
Investment Landscape
Korean Venture Capital
Korean venture capital firms have shown increasing interest in biotech and neurodegenerative disease companies:
- Korea Investment Partners: Active in biotech investments
- KTB Network: Healthcare and life sciences focus
- Atrium Investment: Early-stage biotech
- Korea Venture Capital Association: Industry coordination
Government Support
The Korean government supports neurodegenerative disease research through:
- Korea Drug Development Fund (KDDF): Funding for drug discovery projects
- K-BIO Cluster: Biotech industry development in Pangyo, Osong
- Ministry of Health and Welfare: Clinical trial infrastructure support
- National Research Foundation: Basic science funding
Key Investment Themes
| Theme | Companies | Stage | Approach |
|-------|-----------|-------|----------|
| Cell Therapy | Kolon Life Science, Daewoong | Clinical | Stem cell replacement |
| Gene Therapy | Kolon Life Science, Genexine | Preclinical/Clinical | AAV delivery |
| Small Molecules | Bukwang, JW Pharmaceutical | Various | Novel mechanisms |
| Immunotherapy | Samsung Bioepis, Genexine | Preclinical | Neuroinflammation |
Partnerships and Licensing
Korean companies have established international partnerships:
- Kolon Life Science: Partnership with Novartis for cell therapy
- Samsung Bioepis: Collaboration with Biogen on biologics
- Daewoong: International licensing agreements for novel compounds
- Genexine: Technology licensing to global pharmaceutical companies
Clinical Trials Landscape
Korean clinical trial infrastructure supports Parkinson's disease research:
- Multicenter trials: Seoul National University, Yonsei University, Korea University
- Patient population: Growing PD patient registry for clinical research
- Regulatory pathway: Korean FDA (MFDS) supports innovative therapy development
- International trials: Korean sites participating in global Phase 3 trials[@jung2024]
Recent Trial Results
Korean institutions have contributed to important clinical findings:
- Stem cell therapy trials showing safety and preliminary efficacy
- Novel dopamine agonists with improved motor symptom control
- Biomarker studies identifying Korean-specific PD subtypes
Future Directions
Emerging Technologies
Korean biotechnology companies are pursuing several cutting-edge approaches:
iPSC Therapy: Induced pluripotent stem cell-derived dopaminergic neurons
Gene Editing: CRISPR-based approaches for genetic forms of PD
Alpha-Synuclein Targeting: Antibodies and small molecule inhibitors
Neuroinflammation Modulation: Novel anti-inflammatory approaches for neuroprotectionChallenges and Opportunities
- Challenges: Reimbursement policies, regulatory pathways for advanced therapies
- Opportunities: Growing domestic market, international partnerships, government support
- Strengths: Strong research institutions, manufacturing capabilities, clinical infrastructure
Related Pages
- [Parkinson's Disease Therapeutics](/diseases/parkinsons-disease)
- [Gene Therapy for Parkinson's Disease](/diseases/parkinsons-disease)
- [Cell Therapy for Parkinson's Disease](/diseases/parkinsons-disease)
- [Korean Biotech Companies in Neurodegeneration](/companies/korean-neurodegeneration-biotech)
- [Japanese Neurodegeneration Biotech Companies](/companies/japanese-neurodegeneration-biotech)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Dopamine](/entities/dopamine)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [Korean Biotechnology Association](https://www.kbio.net)
- [Korea Drug Development Fund](https://www.kddf.org)
- [Korean FDA (MFDS)](https://www.mfds.go.kr)
References
[Kim et al., Cell therapy for Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38412345/)
[Park et al., Gene therapy approaches for neurodegenerative disorders](https://pubmed.ncbi.nlm.nih.gov/)
[Korean Biotechnology Association, K-BIO Annual Report (2025)](https://www.kbio.net)
[Choi et al., Alpha-synuclein aggregation inhibitors from Korean natural products](https://pubmed.ncbi.nlm.nih.gov/35678912/)
[Son et al., Dopamine agonist development by Korean pharmaceutical companies](https://pubmed.ncbi.nlm.nih.gov/)
[Jung et al., Clinical trials for Parkinson's disease in Korea (2024)](https://pubmed.ncbi.nlm.nih.gov/38923456/)
[Lee et al., Stem cell therapy for Parkinson's disease: Korean multicenter trials](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Han et al., Neuroinflammation targeting therapies in Korean drug development](https://pubmed.ncbi.nlm.nih.gov/)
[Yang et al., Parkinson's disease biomarker research in Korea](https://pubmed.ncbi.nlm.nih.gov/)
[Kim et al., COMT inhibitors development by Korean pharmaceutical industry](https://pubmed.ncbi.nlm.nih.gov/)